Castle Biosciences, Inc. - Common stock (NQ:CSTL)

33.48 -3.17 (-8.66%)

Delayed Quote Updated: 3:20 PM EDT, Oct 6, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Castle Biosciences, Inc. - Common stock

< Previous 1 2

...

7 8 9 10 11 12 13 14 Next >

Castle Biosciences Reports First Quarter 2022 Results

May 09, 2022

From Castle Biosciences, Inc.

Via Business Wire

Camille Schrier, Miss America 2020, and Castle Biosciences Partner to Expand Awareness of Genetic Testing in Depression and Anxiety

May 06, 2022

From Castle Biosciences, Inc.

Via Business Wire

Castle Biosciences Recognizes Skin Cancer Awareness Month through Its Support of Patient-Focused Initiatives

May 03, 2022

From Castle Biosciences, Inc.

Via Business Wire

Earnings Scheduled For February 28, 2022 ↗

February 28, 2022

Companies Reporting Before The Bell • Lexicon Pharmaceuticals (NASDAQ:LXRX) is estimated to report earnings for its fourth quarter. • Praxis Precision Medicine (...

Via Benzinga

Castle Biosciences Announces Expanded U.S. Federal Supply Schedule Contract Covering Its Entire Dermatologic Cancer Portfolio of Tests

April 29, 2022

From Castle Biosciences, Inc.

Via Business Wire

Data from Independent, Pooled Analysis Show Significantly Improved Risk Predictions Over Clinical Variables for TissueCypher® Barrett’s Esophagus Test and Ability to Identify Patients at High Risk of Progressing to Esophageal Cancer

April 27, 2022

From Castle Biosciences, Inc.

Via Business Wire

Castle Biosciences Completes Acquisition of AltheaDx

April 26, 2022

From Castle Biosciences, Inc.

Via Business Wire

Castle Biosciences to Release First Quarter 2022 Financial Results and Host Conference Call on Monday, May 9

April 25, 2022

From Castle Biosciences, Inc.

Via Business Wire

Expanded SEER Registries Dataset Shows Improved Survival for DecisionDx®-Melanoma Tested Patients Compared to Untested Patients

April 21, 2022

From Castle Biosciences, Inc.

Via Business Wire

Castle Biosciences to Present Data at the 18th European Association of Dermato Oncology (EADO) Congress

April 20, 2022

From Castle Biosciences, Inc.

Via Business Wire

Castle Biosciences Presents Data on Its Inflammatory Skin Disease Pipeline Test at the 4th Annual Revolutionizing Atopic Dermatitis (RAD) Conference

April 18, 2022

From Castle Biosciences, Inc.

Via Business Wire

51 Biggest Movers From Yesterday ↗

April 06, 2022

Gainers Sunshine Biopharma, Inc. (NASDAQ: SBFM) shares surged 148.2% to close at $5.61 on Tuesday after the company announced that two of its designed mRNA molecules are...

Via Benzinga

Castle Biosciences to Present at the 21st Annual Needham Virtual Healthcare Conference

April 05, 2022

From Castle Biosciences, Inc.

Via Business Wire

Castle Biosciences Adds Mental Health Testing Solutions Via AltheaDx Acquisition ↗

April 05, 2022

Castle Biosciences Inc (NASDAQ: CSTL) has agreed to acquire AltheaDx Inc, a commercial-stage molecular diagnostics company,

Via Benzinga

Castle Biosciences to Acquire AltheaDx

April 04, 2022

From Castle Biosciences, Inc.

Via Business Wire

Castle Biosciences Receives Advanced Diagnostic Laboratory Test (ADLT) Status for TissueCypher® Barrett’s Esophagus Test from the Centers for Medicare & Medicaid Services (CMS)

March 29, 2022

From Castle Biosciences, Inc.

Via Business Wire

Data to be Presented at the 2022 American Academy of Dermatology (AAD) Annual Meeting Demonstrate Ability of DecisionDx®-Melanoma and DecisionDx®-SCC to Inform Clinical Decision Making

March 25, 2022

From Castle Biosciences, Inc.

Via Business Wire

Castle Biosciences: Q4 Earnings Insights ↗

February 28, 2022

Castle Biosciences (NASDAQ:CSTL) reported its Q4 earnings results on Monday, February 28, 2022 at 04:05 PM. Here's what investors need to know about the announcement. Earnings...

Via Benzinga

Castle Biosciences to Release Fourth Quarter and Full-Year 2021 Financial Results and Host Conference Call on Monday, Feb. 28, 2022

February 14, 2022

From Castle Biosciences, Inc.

Via Business Wire

Castle Biosciences to Present at the 11th Annual SVB Leerink Global Healthcare Conference

February 07, 2022

From Castle Biosciences, Inc.

Via Business Wire

Introduction of Innovative PCR-Based Detection Methods Surges Fueled by Pandemic and Other Diseases

February 18, 2022

Palm Beach, FL – February 18, 2022 – FinancialNewsMedia.com News Commentary – PCR testing and the COVID-19 diagnostic testing market has, unexpectantly, been growing at a substantial rate the past few...

Via FinancialNewsMedia

Topics Intellectual Property

Castle Biosciences Collaborates with the National Cancer Institute to Link DecisionDx®-Melanoma Testing Data with SEER Registries’ Cutaneous Melanoma Cases

February 03, 2022

From Castle Biosciences, Inc.

Via Business Wire

Castle Biosciences Named a Winner of the 2022 Top Workplaces USA Award

February 02, 2022

From Castle Biosciences, Inc.

Via Business Wire

Castle Biosciences to Present Data at Maui Derm for Dermatologists 2022

January 24, 2022

From Castle Biosciences, Inc.

Via Business Wire

Recently Published Data Confirm DecisionDx®-SCC as a Significant and Independent Risk-Stratification Tool in Patients with Squamous Cell Carcinoma and One or More Risk Factors

January 13, 2022

From Castle Biosciences, Inc.

Via Business Wire

Data Published in Ocular Oncology and Pathology Demonstrates Highly Accurate Performance of DecisionDx®-UMSeq for Patients with Uveal Melanoma

January 12, 2022

From Castle Biosciences, Inc.

Via Business Wire

Castle Biosciences Announces Preliminary Fourth Quarter and Full-Year 2021 Results

January 10, 2022

From Castle Biosciences, Inc.

Via Business Wire

Castle Biosciences to Present at the 24th Annual Needham Growth Conference

December 28, 2021

From Castle Biosciences, Inc.

Via Business Wire

Benzinga's Top Ratings Upgrades, Downgrades For January 7, 2022 ↗

January 07, 2022

Upgrades According to Wolfe Research, the prior rating for CVR Energy Inc (NYSE:

Via Benzinga

Castle Biosciences Completes Acquisition of Cernostics

December 06, 2021

From Castle Biosciences, Inc.

Via Business Wire

< Previous 1 2

...

7 8 9 10 11 12 13 14 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.